Regulus Therapeutics, the San Diego-based developer of microRNA therapies, said today that it has obtained exclusive rights from New York University to develop treatments against a couple of microRNA targets (miR-33a and miR-33b) which are thought to have potential to affect athersclerosis and metabolic syndrome. Financial terms of the license weren’t disclosed.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
